Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | TYMP | P19971 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360743 | 0.77 | KMT2A (0.43) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL28818918 | 0.74 | KMT2A (0.48) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL21754476 | 0.73 | KMT2A (0.37) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL3835020 | 0.71 | LMNA (0.43) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL27470889 | 0.71 | KMT2A (0.39) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL296106 | 0.70 | LMNA (0.48) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL27795012 | 0.70 | KMT2A (0.44) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL16473550 | 0.70 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL11107422 | 0.69 | LMNA (0.43) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL7459874 | 0.69 | KMT2A (0.38) | KMT2ALMNATHRBCYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | SLC39A14, SLC39A11, TMEM14C | KMT2A 2870/4885LMNA 2646/4885THRB 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.